BZBu Qiang Zhuang

Bu Qiang Zhuang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bu Qiang Zhuang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Song Liu

    Cancer Interventional Center, Linyi Cancer Hospital

    2 shared publications
  • Fei Gao

    Affiliation Department of Intervention, The Second Hospital of Dalian Medical University, Dalian, Liaoning Province, China

    1 shared publication
  • Guang Sheng Zhao

    Affiliation Minimally Invasive Interventional Diagnosis and Treatment Center, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning Province, China

    1 shared publication
  • Guangji Yu

    Cancer Interventional Center, Linyi Cancer Hospital

    1 shared publication
  • Guangsheng Zhao

    Minimally Invasive Interventional Diagnosis and Treatment Center, Affiliated Zhongshan Hospital of Dalian University, Dalian, China

    1 shared publication
  • Hou Ze Zhou

    Affiliation Dalian Medical University, Dalian, Liaoning Province, China

    1 shared publication

Latest Publications

  • Open Access

    Efficacy and safety of CalliSpheres drug-eluting bead transarterial chemoembolization for unresectable gastrointestinal stromal tumor liver metastases after failure of targeted therapy: a multicenter retrospective study

    by Song Liu, Ting Chen, Shunhang Yin, Guangji Yu, Qingdong Wang, Long Li, Guangsheng Zhao, Lei Zhang, Buqiang Zhuang

    Objective: To evaluate the clinical efficacy and safety of CalliSpheres drug-eluting bead transarterial chemoembolization (DEB-TACE) in patients with unresectable gastrointestinal stromal tumor (GIST) liver metastases after the failure of targeted therapy. Methods: 77 patients with unresectable GIST liver metastases who had failed at least two lines of targeted therapy were retrospectively enrolled from three centers between January 2022 to December 2024. Based on their treatment regimen, patients were divided into an observation group (n=34) and a control group (n=43). The control group continued receiving tyrosine kinase inhibitors (TKIs) or best supportive care (BSC). The observation group underwent DEB-TACE followed by TKI therapy or BSC. Tumor response was assessed using the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Overall survival (OS), progression-free survival (PFS), and adverse events during treatment were recorded and analyzed. Results: At the first efficacy evaluation, the observation group exhibited an objective response rate (ORR) of 94.12% (10 complete response [CR], 22 partial response [PR]) and a disease control rate (DCR) of 100%. In the control group, the ORR was 4.65% (2 PR) and the DCR was 39.53%. The median PFS (liver) was significantly longer in the observation group (11.0 months) than in the control group (5.0 months; P < 0.001). The median OS was also longer in the observation group (18.0 months vs. 12.0 months; P < 0.001). Prognostic analysis indicated that better baseline liver function, fewer prior lines of therapy, and DEB-TACE treatment were associated with improved outcomes. Adverse events in the observation group were primarily related to post-embolization syndrome and transient liver injury, with no increase in targeted therapy-related toxicity. Conclusion: DEB-TACE demonstrates favorable efficacy and a manageable safety profile in patients with unresectable GIST liver metastases after targeted therapy failure, representing a safe and feasible treatment option worthy of clinical application.

  • Open Access

    The radioactive 3D-printed template-assisted CT-guided 125I seed implantation for refractory bone metastases: A multicenter retrospective analysis of efficacy, safety, and immune function changes

    by Guang Sheng Zhao, Hou Ze Zhou, Qiu Shi Wang, Xin Yu Zhou, Jin Bo Sun, Fei Gao, Ruo Yu Wang, Zhe Wang, Jun Zhou, Song Liu, et al.

    Objective: To comprehensively evaluate the efficacy and safety of three-dimensional (3D)-printed template-assisted CT-guided 125 I seed implantation for refractory bone metastases in a multicenter cohort, to explore its impact on systemic immune function and to identify potential mechanisms. Methods: This retrospective analysis was conducted on 253 patients with refractory bone metastases who were continuously admitted to Affiliated Zhongshan Hospital of Dalian University, Linyi Cancer Hospital, The Affiliated Hospital of Xuzhou Medical University, Dalian Public Health Clinical Center, and The Second Hospital of Dalian Medical University. The onset time and the duration of pain relief were recorded. The therapeutic efficacy was evaluated by comparing pre- and postoperative Daily Oral Morphine Equivalent Consumption (OMEC), Numerical Rating Scale (NRS) for pain, Quality of Life (QOL) scores, and Karnofsky Performance Status (KPS) scores, as well as by measuring the quantitative changes in target lesion volume and Hounsfield unit (HU) values on imaging before and after the procedure. According to Response Evaluation Criteria in Solid Tumors version 1.1, the objective response rate (ORR) and disease control rate (DCR) were calculated to evaluate tumor response. Flow cytometry was used to detect and compare pre- and postoperative proportions of CD3 + CD16 + /CD56 + natural killer-like T (NKT) cells and CD3 − CD16 + /CD56 + NK cells, interleukin (IL)-17A level, and CD4 + /CD8 + T-cell ratio, to assess the changes in host immune function after treatment. Local progression-free survival (LPFS) and overall survival (OS) were calculated, and adverse events were documented. Results: All patients completed 3D-printed template-assisted CT-guided 125 I seed implantation, with a procedural success rate of 100%. The clinical symptoms improved after treatment; the median onset time to pain relief was 3.5 days, and the median duration of relief was 10.7 months. The OMEC values and the NRS scores were significantly lower than those before procedure ( P < 0.05), whereas QOL and KPS scores were significantly higher ( P < 0.05). The radiologic evaluation showed that ORR and DCR were 42.29% and 69.56%, and 79.05% and 88.93%, respectively, at 1 and 6 months after implantation. The target lesion volumes reduced significantly ( P < 0.05), whereas the HU value increased significantly ( P < 0.05), indicating tumor necrosis and osteoblastic repair. The median LPFS was 14.1 months, and the median OS was 19.5 months. The immune function analysis revealed enhanced antitumor immune response, reflected by significant increases in the proportions of NKT cells, NK cells, and CD8 + T cells, a decrease in IL-17A level, and a trend toward normalization of the CD4 + /CD8 + ratio ( P < 0.05). Adverse events mainly consisted of transient local pain of Common Terminology Criteria for Adverse Events grades 1–2. No uncontrollable major bleeding, needle-track seeding, or other severe complication, and no treatment-related death occurred. Conclusions: The 3D-printed template-assisted CT-guided 125 I seed implantation was a safe and effective treatment for refractory bone metastases. It provided durable local tumor control and pain relief, and was accompanied by systemic immunological changes. These changes correlated with clinical improvements, suggesting a potential immunological component to the therapeutic effect. This therapy therefore provided a promising treatment strategy for refractory bone metastases.